Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 11/20 | 0.60 |
| ▸ | LCK | P06239 | 4/20 | 0.60 |
| ▸ | CSF1R | P07333 | 4/20 | 0.60 |
| ▸ | ABL1 | P00519 | 4/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.60 |
| ▸ | FLT1 | P17948 | 3/20 | 0.60 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.60 |
| ▸ | PRKACA | P17612 | 2/20 | 0.60 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | PAK4 | O96013 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30248298 | 1.00 | GAA (0.61) | GAAPDPK1KDRLCKCSF1R | |
| SCHEMBL16681068 | 0.84 | KDR (0.65) | GAAPDPK1KDRLCKCSF1R | |
| SCHEMBL628649 | 0.79 | PDPK1 (0.66) | GAAPDPK1KDRLCKCSF1R | |
| SCHEMBL30065304 | 0.79 | PDPK1 (0.66) | GAAPDPK1KDRLCKCSF1R | |
| SCHEMBL12928484 | 0.76 | PDPK1 (0.61) | GAAPDPK1KDRLCKCSF1R | |
| SCHEMBL760018 | 0.76 | PDPK1 (0.61) | GAAPDPK1KDRLCKCSF1R | |
| SCHEMBL569660 | 0.76 | GAA (0.61) | GAAPDPK1KDRLCKCSF1R | |
| SCHEMBL10368038 | 0.76 | PDPK1 (0.61) | GAAPDPK1KDRLCKCSF1R | |
| SCHEMBL186280 | 0.76 | GAA (1.00) | GAAPDPK1KDRLCKCSF1R | |
| SCHEMBL7736987 | 0.76 | PDPK1 (0.61) | GAAPDPK1KDRLCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818683-B | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2023-04-14 | — | — | CN | disclosed |
| CN-115484826-A | Compositions and methods for controlling fungal diseases in plants | FMC公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-114258261-A | Apparatus and method for reducing dust development in precision drilling | 先正达参股股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114072384-A | Microbicidal picolinamide derivatives | 先正达农作物保护股份公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-01 | — | — | US | disclosed |
| CN-113939510-A | Microbicidal derivatives | 先正达农作物保护股份公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-113906034-A | Microbicidal derivatives | 先正达农作物保护股份公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-113874353-A | Microbicidal derivatives | 先正达农作物保护股份公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3260454-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-6610677-B2 | Enhancing glycogen synthesis, lowering blood levels of glucose, treating colon, ovarian, or breast cancer, treating diabetes, treating schizophrenia | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-26 | — | — | US | disclosed |
| US-20030130328-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6559173-B1 | organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | ALLERGAN, INC. | 2003-05-06 | — | — | US | disclosed |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | disclosed |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| WO-2003026650-A1 | 3-(HETEROARYLAMINO)METHYLENE-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3A | GAA 3700/4885PDPK1 178/4885KDR 1008/4885 |
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | GAA 3060/4885PDPK1 2485/4885KDR 847/4885 |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | MAP3K20, CDK2, MAP2K2 | GAA 2613/4885PDPK1 139/4885KDR 942/4885 |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GAA 3354/4885PDPK1 230/4885KDR 1239/4885 |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GAA 4018/4885PDPK1 159/4885KDR 1060/4885 |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | GAA 3060/4885PDPK1 2485/4885KDR 847/4885 |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GAA 4584/4885PDPK1 239/4885KDR 1906/4885 |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, GSK3A, GSKIP | GAA 3623/4885PDPK1 10/4885KDR 2419/4885 |
| US-20030130328-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | GAA 2732/4885PDPK1 20/4885KDR 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.